Interventional effect of low molecular weight heparin on mice with experimental hepatic fibrosis

doi:10.12092/j.issn.1009-2501.2019.05.005

Abstract

Abstract:

AIM: To investigate the interventional effect of low molecular weight heparin on mice with hepatic fibrosis caused by carbon tetrachloride (CCl4). METHODS: Thirty mice were randomly divided into three groups: normal control group (intraperitoneally injection of olive oil for 8 weeks, n=10), model group (intraperitoneally injection of CCl4 for 8 weeks, n=10) and interventional group (intraperitoneally injection of CCl4 and subcutaneous injection of low molecular weight heparin for 8 weeks, n=10). All animals were sacrificed at the end of week 8, and blood samples and liver tissue samples were obtained. The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL) and hyaluronicacid (HA) were detected. Liver pathology morphology and collagen deposition were observed by HE staining, masson-trichrome staining and PCR staining. The expression of α-smooth muscle actin (α-SMA) in hepatic tissue was detected by immunohistochemistry. The expression of α-SMA and collagen type Ⅰ(COL-Ⅰ) mRNA in the hepatic tissue was quantified by real time PCR. RESULTS:Compared with control group, the serum level of ALT, AST, TBIL, DBIL and HA, the liver collagen deposition, the hepatic tissue expression of α-SMA and the hepatic tissue expression of α-SMA and COL-Ⅰ mRNA in both model group and interventional group were all significantly higher(all P＜0.05). Compared with model group, the serum level of ALT, AST, TBIL, DBIL and HA, the liver collagen deposition, the hepatic tissue expression of α-SMA and the hepatic tissue expression of α-SMA and COL-Ⅰ mRNA in interventional group were all significantly decreased (all P＜0.05).CONCLUSION: Low molecular weight heparin can attenuate the progression of mice hepatic damage and fibrosis caused by CCl4. The mechanism may be related with the anticoagulation of low molecular weight heparin.

Key words: low molecular weight heparin, liver fibrosis, animal model, α-smooth muscle actin

CLC Number:

R332
R575.2

ZHENG Qiongna, WU Qiaoqiao, MA Zhele, ZHANG Xianfei, GAN Fangmin, KONG Qingming. Interventional effect of low molecular weight heparin on mice with experimental hepatic fibrosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 511-516.

References

［1］Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population［J］. JAMA Intern Med, 2016, 176(1):65-73.
［2］Hakuno D, Kimura M, Ito SHepatokine, et al. α1-Microglobulin signaling exacerbates inflammation and disturbs fibrotic repair in mouse myocardial infarction［J］. Sci Rep, 2018, 8(1):16749.
［3］Nakao T, Arii S, Kaido T, et al. Heparin accclcrates liver regeneration following portal branch ligation in normal and cirrhotic rats with increased plasma hepatocyte growth factor levels［J］. J Hepatol, 2002,37(1):87-92.
［4］Yan Y, Guan C, Du S, et al. Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis［J］. Front Pharmacol, 2017, 8:514.
［5］Tripodi A, Primignani M, Braham S, et al. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists［J］. Dig Liver Dis, 2016, 48(10):1208-1213.
［6］Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients ［J］. J Hepatol, 2016, 64(4):773-780.
［7］Hui J, Gao J, Wang Y, et al. Panax notoginseng saponins ameliorates experimental hepatic fibrosis and hepatic stellate cell proliferation by inhibiting the Jak2/Stat3 pathways［J］. J Tradit Chin Med, 2016, 36(2):217-224.
［8］潘旭旺, 童永喜, 庄让笑, 等. 芹菜素纳米乳抗CCl-4诱导大鼠肝纤维化作用实验研究［J］. 中华中医药学刊, 2017, 35(6):1482-1485.
［9］Adatya S, Sunny R, Fitzpatrick MJ, et al. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.［J］. J Heart Lung Transplant, 2016, 35(11):1311-1320.
［10］Annika W, Victoria A, Debashis H, et al. CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism:［J］. Gut, 2016, 65(7):1175-1185.
［11］Cerini F, Vilaseca M, Lafoz E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats ［J］. J Hepatol, 2016, 64(4):834-842.
［12］Simonetto DA, Yang H, Yin M, et al. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces ［J］. Hepatology, 2015, 61(2):648-659.
［13］Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis ［J］. Gut, 2003, 52(3):404-409.
［14］徐列明. 中医药抗肝纤维化疗效评价的探索［J］. 临床肝胆病杂志, 2017, 33(5):825-828.

[1]	WEI Feng, HE Yang, FAN Zhiqiang, LIU Shikun, OUYANG Linqi. Inhibitory effect of flufenidone on TGF-β1/Smads pathway in hepatocytes of rats with diethylnitrosamine (DEN)-induced liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 739-746.
[2]	CHEN Sen, FAN Chang, ZHANG Jiafu, MA Yanzhen, JIANG Hui. The mechanism of Shugan Jianpi Formula regulating TLR4/MyD88/NLRP3 signaling axis to inhibit pyroptosis in mice with liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1081-1089.
[3]	QIN Wenjie, YANG Zhiling, CAO Ailin, GAO Hang, JIANG Xianrui, SHEN Yue, QIAN Jiao. Advances in the study of new oral anticoagulants in cancer-associated venous thromboembolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 823-828.
[4]	CAO Zhiwen, HU Weihua. Effects of intrauterine perfusion of growth hormone on thin endometrium [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 983-988.
[5]	LIU Jiangang, WANG Xiaobo. Expression and significance of TRPV1 and TRPA1 in DRG neurons of rats with endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 617-621.
[6]	ZHANG Wei-Jian, XU Jian-Hua, ZHANG Jie-Min, CHEN Jin-Mei, CHEN Xiu-Ying, YANG Mei-Chun, 吕Wen-Long , HONG Jin-Sheng. Build up acute radiation-induced lung injury model in mice and observe the protect effect of Glycyrrhetic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(6): 629-633.
[7]	HUA Xiao-ping, ZHANG Li, HUANG Li, TAN Zheng-huai, CHEN Zhuang. Morphological differences of liver between two liver fibrosis models induced by dimethylnitrosamine and thioacetamide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 747-751.
[8]	YE Lei, LI Jian-shuang, CHEN Zhi-yun, YAN Mao-xiang, HE Pei-hui. The role of ginkgo biloba extract on the hepatic GRP78 and CHOP expression in rats with liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 377-380.
[9]	YANG Lin-cheng, HE Yi-lei, LI Wei-dong. Research advances of the leukemia animal models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1416-1421.
[10]	ZHUANG Rang-xiao, WANG Fu-gen, SHAO Yi-dan, FANG Hong-ying, SUN Jing-jing, XI Jian-jun, PAN Jin-ming, LIANG Wei-feng, LIU Shou-rong. Experimental study of acetylcysteine magnesium-glycyrrhizin fine antipode dimers on rat liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1337-1341.
[11]	FU Ling-zhu, ZHENG Ting, ZHANG Yong-sheng. Advances in understanding the role of TGF-β/Smad signalling pathways in the pathogenesis of liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1189-1195.
[12]	ZHU Yan-hong, CHEN Zhen, QIAN Zhi-yu, HU Hui, CHENG Wen-yuan. Effects of crocetin on proliferation and collagen synthesis of hepatic stellate cell [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 841-846.
[13]	CHENG Zhi-yun, PENG Jun-chun, LV Ying-hui. Role of epithelial-mesenchymal transition in the liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 928-936.
[14]	JIANG Hui, GAO Jia-rong, CHEN Jin-feng, LIU Yong. Hepatoprotective effect of Panax notoginseng saponins in hepatic fibrosis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1116-1120.
[15]	LIU Xing, WANG Meng-ya. Improving effects of gastrodin on learning and memory in model rats with Alzheimer disease induced by intra-hippocampal Aβ_1-40 injection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 408-411.